Abstract
Part III of the article that describes confirmatory adaptive platform trial (CAPT) design for COVID-19 treatment development. We continue with the section on statistical methods for CAPT design, covering topics on sequential p-value and monitoring, point estimate and confidence interval, multiplicity in hypothesis testing, missing data handling, and use of non-concurrent controls. We finish the article with discussion on controversy of stochastic curtailment, inappropriateness of adaptive Bayesian design, and free software for group sequential designs.
| Original language | American English |
|---|---|
| Journal | |
| State | Published - May 11 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Disciplines
- Biostatistics
- Environmental Public Health
- Epidemiology
- Public Health
Fingerprint
Dive into the research topics of 'Statistical Considerations for Clinical Trials During COVID-19: Confirmatory Adaptive Platform Trial (CAPT) Design for COVID-19 Treatment (Part III)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver